Literature DB >> 26411549

Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma.

Eric H Kim1, Seth A Strope2.   

Abstract

The American Urological Association and the National Comprehensive Cancer Network guidelines regarding postoperative surveillance for renal cell carcinoma (RCC) have provided a standardized framework for imaging following nephrectomy. These stage-stratified recommendations are based on retrospective studies that identified the timeline and location of RCC recurrences. However, the simplified and generalizable protocols offered by the American Urological Association and the National Comprehensive Cancer Network are not without limitations. Studies have found that RCC recurrences continue to be missed even with perfect compliance to these protocols and that RCC recurrences occur not infrequently after the required surveillance window of 5 years. Furthermore, recent studies evaluating the use of adjuvant systemic therapy in patients who are at a high risk for RCC recurrence or metastasis after nephrectomy have yielded disappointing results. This calls into question what interventions we can offer patients to improve survival once RCC recurrences are detected during postoperative surveillance; an effective surveillance strategy requires effective treatment options. The future of personalized medicine with genetic profiling of patients with RCC may offer a potential solution by providing better risk stratification to determine the intensity of surveillance imaging as well as to determine which patients will actually derive survival benefit from intervention on recurrent disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnostic imaging; Recurrence; Renal cell carcinoma; Surveillance

Mesh:

Year:  2015        PMID: 26411549      PMCID: PMC4654665          DOI: 10.1016/j.urolonc.2015.08.008

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  25 in total

1.  Cancer drugs in the United States: Justum Pretium--the just price.

Authors:  Hagop M Kantarjian; Tito Fojo; Michael Mathisen; Leonard A Zwelling
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

2.  Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma.

Authors:  Steffen Schrodter; Oliver W Hakenberg; Andreas Manseck; Steffen Leike; Manfred P Wirth
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

3.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.

Authors:  Samira A Brooks; A Rose Brannon; Joel S Parker; Jennifer C Fisher; Oishee Sen; Michael W Kattan; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; C Ryan Miller; Matthew E Nielsen; W Kimryn Rathmell
Journal:  Eur Urol       Date:  2014-02-25       Impact factor: 20.096

4.  Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines.

Authors:  Suzanne B Stewart; R Houston Thompson; Sarah P Psutka; John C Cheville; Christine M Lohse; Stephen A Boorjian; Bradley C Leibovich
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

5.  Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.

Authors:  M Aitchison; C A Bray; H Van Poppel; R Sylvester; J Graham; C Innes; L McMahon; P A Vasey
Journal:  Eur J Cancer       Date:  2013-09-25       Impact factor: 9.162

6.  Kidney cancer, version 3.2015.

Authors:  Robert J Motzer; Eric Jonasch; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Sam S Chang; Toni K Choueiri; Brian A Costello; Ithaar H Derweesh; Shilpa Gupta; Steven L Hancock; Jenny J Kim; Timothy M Kuzel; Elaine T Lam; Clayton Lau; Ellis G Levine; Daniel W Lin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Elizabeth R Plimack; Edward N Rampersaud; Bruce G Redman; Charles J Ryan; Joel Sheinfeld; Brian Shuch; Kanishka Sircar; Brad Somer; Richard B Wilder; Mary Dwyer; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2015-02       Impact factor: 11.908

7.  Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).

Authors:  Sabine Brookman-May; Matthias May; Shahrokh F Shariat; Evanguelos Xylinas; Christian Stief; Richard Zigeuner; Thomas Chromecki; Maximilian Burger; Wolf F Wieland; Luca Cindolo; Luigi Schips; Ottavio De Cobelli; Bernardo Rocco; Cosimo De Nunzio; Bogdan Feciche; Michael Truss; Christian Gilfrich; Sascha Pahernik; Markus Hohenfellner; Stefan Zastrow; Manfred P Wirth; Giacomo Novara; Marco Carini; Andrea Minervini; Claudio Simeone; Alessandro Antonelli; Vincenzo Mirone; Nicola Longo; Alchiede Simonato; Giorgio Carmignani; Vincenzo Ficarra
Journal:  Eur Urol       Date:  2012-06-22       Impact factor: 20.096

8.  A multigene assay identifying distinct prognostic subtypes of clear cell renal cell carcinoma with differential response to tyrosine kinase inhibition.

Authors:  Yukti Choudhury; Xiaona Wei; Ying-Hsia Chu; Lay Guat Ng; Hui Shan Tan; Valerie Koh; Aye Aye Thike; Eileen Poon; Quan Sing Ng; Chee Keong Toh; Ravindran Kanesvaran; Puay Hoon Tan; Min-Han Tan
Journal:  Eur Urol       Date:  2014-07-10       Impact factor: 20.096

9.  Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

Authors:  Nils Kroeger; Toni K Choueiri; Jae-Lyn Lee; Georg A Bjarnason; Jennifer J Knox; Mary J MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishamayan; Sun-Young Rha; Sumanta K Pal; Takeshi Yuasa; Frede Donskov; Neeraj Agarwal; Min-Han Tan; Aristotelis Bamias; Christian K Kollmannsberger; Scott A North; Brian I Rini; Daniel Y C Heng
Journal:  Eur Urol       Date:  2013-07-30       Impact factor: 20.096

10.  Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort.

Authors:  Christopher M Russell; Patrick N Espiritu; Wassim Kassouf; Thomas Schwaab; David D Buethe; Jasreman Dhilon; Wade J Sexton; Michael Poch; Julio M Powsang; Simon Tanguay; Madhur Nayan; Hazem Alsaadi; Michael I Hanzly; Philippe E Spiess
Journal:  J Urol       Date:  2014-02-14       Impact factor: 7.450

View more
  3 in total

1.  Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell.

Authors:  Lin Fang; Qian Cheng; Wenshun Liu; Jie Zhang; Yan Ge; Qi Zhang; Liantao Li; Junjie Liu; Junnian Zheng
Journal:  Cancer Biol Ther       Date:  2016-05-19       Impact factor: 4.742

2.  Prognostic role of myoferlin expression in patients with clear cell renal cell carcinoma.

Authors:  Dae Hyun Song; Gyung Hyuck Ko; Jeong Hee Lee; Jong Sil Lee; Jung Wook Yang; Min Hye Kim; Hyo Jung An; Myoung Hee Kang; Kyung Nyeo Jeon; Dong Chul Kim
Journal:  Oncotarget       Date:  2017-10-06

3.  Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.

Authors:  Sohyun Park; Ho-Young Lee; Sangchul Lee
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-09       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.